|Bid||73.87 x 800|
|Ask||75.00 x 900|
|Day's Range||73.54 - 77.32|
|52 Week Range||8.90 - 189.89|
|Beta (5Y Monthly)||1.62|
|PE Ratio (TTM)||8.38|
|Earnings Date||May 06, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||89.00|
Investors might have begun to worry that Fulgent Genetics' (NASDAQ: FLGT) freefall in recent months would never end. The genetic testing company's shares have plunged more than 50% from the highs set earlier this year. Fulgent announced its first-quarter results after the market closed Thursday.
At this time, I would like to turn the conference over to Nicole Borsje with investor relations. On the call today are Ming Hsieh, chief executive officer; Paul Kim, chief financial officer; and Brandon Perthuis, chief commercial officer.
Fulgent Genetics, Inc. (NASDAQ: FLGT) ("Fulgent" or the "company"), a technology company providing large-scale COVID-19 testing services and comprehensive testing solutions through its scalable technology platform, today announced financial results for its first quarter ended March 31, 2021.